AtaiBeckley Inc ATAI:NASDAQ
RT Quote | Last NYSE Arca, VOL From CTA | USD
After Hours: Last | 7:54 PM EDT4.45
-0.08 (-1.77%)
-0.08 (-1.77%)Volume
57,834
Close
4.53-0.28 (-5.82%)
-0.28 (-5.82%)Volume
4,741,610
52 week range
2.00 - 6.75
- Open4.78
- Day High4.78
- Day Low4.46
- Prev Close4.81
- 52 Week High6.75
- 52 Week High Date10/20/25
- 52 Week Low2.00
- 52 Week Low Date06/24/25
Latest On AtaiBeckley Inc
Key Stats
- Market Cap1.668B
- Shares Out368.17M
- 10 Day Average Volume5.08M
- Dividend-
- Dividend Yield-
- Beta1.60
Latest On AtaiBeckley Inc
KEY STATS
- Open4.78
- Day High4.78
- Day Low4.46
- Prev Close4.81
- 52 Week High6.75
- 52 Week High Date10/20/25
- 52 Week Low2.00
- 52 Week Low Date06/24/25
- Market Cap1.668B
- Shares Out368.17M
- 10 Day Average Volume5.08M
- Dividend-
- Dividend Yield-
- Beta1.60
RATIOS/PROFITABILITY
- EPS (TTM)-2.23
- P/E (TTM)-2.03
- Fwd P/E (NTM)-10.94
- EBITDA (TTM)-121.929M
- ROE (TTM)-378.29%
- Revenue (TTM)3.488M
- Gross Margin (TTM)-
- Net Margin (TTM)-19,021.90%
- Debt To Equity (MRQ)-
EVENTS
- Earnings Date08/10/2026(est)
- Ex Div Date-
- Div Amount-
- Split Date-
- Split Factor-
Content From Our Affiliates
Related Video
watch now
Profile
MOREAtaiBeckley Inc is a clinical-stage biotechnology company focused on developing rapid-acting, durable and convenient mental health treatments. The Company’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 (R-MDMA HCI) for social anxiety disorder. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for...
Srinivas Rao M.D., Ph.D.
Chief Executive Officer, Co-Founder, Interim Managing Director
Gerd Kochendoerfer Ph.D.
Chief Operating Officer
Michael Faerm
Chief Financial Officer
Address
New York, NY
10119
United States